SS-31

SS-31 – Benefits & Side Effects

SS-31 – Protocol

SS-31 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

SS-31 – Identification

Common Names: SS-31, Elamipretide, Bendavia, MTP-131, Ocuvia, Mitochondrial-Targeted Peptide 131

CAS Number: 736992-21-5 (free base); 1334953-95-5 (acetate salt form); 72244098-12-0 (hydrochloride salt form)

Molecular Formula: C₃₂H₄₉N₉O₅ (free base); varies with salt form

Molecular Weight: 639.8 g/mol (free base); 679.8 g/mol (acetate salt); approximately 676 g/mol (HCl salt form)

Origin & Type Classification:

• Source: Synthetic; engineered cardiolipin-targeting peptide

• Biosynthesis: Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS)

• Functional Class: Mitochondrial-targeted peptide; cardiolipin stabilizer; ATP synthesis enhancer; ROS scavenger; antioxidant; therapeutically-investigated peptide

Additional Information:

• Amino Acid Sequence: H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH₂ (N-terminal hydrogen, D-arginine at position 1, C-terminal primary amide)

• Sequence Abbreviation: RXKF (where R=D-Arg, X=Tyr(2,6-diMe), K=Lys, F=Phe)

• Sequence Length: 4 amino acids (tetrapeptide)

• Structural Type: Linear tetrapeptide with alternating aromatic-cationic residues; N-terminal D-arginine (unusual D-amino acid); C-terminal primary amide; dimethylated tyrosine at position 2

• D-Arginine Configuration: Unusual D-form (not L-form) enables enhanced membrane penetration and mitochondrial targeting

• Dimethyltyrosine: 2,6-dimethylation of tyrosine (position 2) increases hydrophobic interactions with cardiolipin acyl chains

• Cardiolipin Binding Affinity: High-affinity binding through dual hydrophobic-electrostatic interactions; dissociation constant in nanomolar to picomolar range

• Mitochondrial Accumulation: Accumulates to concentrations 5000-fold higher in inner mitochondrial membrane than cytoplasm through electrical gradient-driven targeting

• Respiratory Complex Interaction: Binds to multiple respiratory chain components including cytochrome c oxidase (Complex IV), ATP synthase, and other OXPHOS complexes

• Plasma Half-Life: 4 hours (intravenous administration in dogs); 1-2 hours (reported range across studies)

• Blood-Brain Barrier Permeability: BBB-permeable enabling CNS accumulation for neuroprotection

• Renal Elimination: Primarily renal excretion with minimal hepatic metabolism

• Physical Form: White to off-white lyophilized powder; ≥95-98% purity via HPLC

• Salt Form: Available as free base, acetate salt, or hydrochloride salt; various pharmaceutical formulations

• Water Solubility: Excellent water solubility enabling parenteral administration (IV infusion)

• Clinical Administration Route: Intravenous infusion over 4 hours at dose range 0.01-0.25 mg/kg/h

• Known Synonyms: Mitochondrial-targeted peptide antioxidant SS-31, Cardiolipin-binding peptide, Elamipretide (INN/USAN)

• Supplier Identification: PubChem CID 11764719; DrugBank DB15053; WHO-DD designation

Database Links:

• PubChem: CID 11764719 (Elamipretide)

• UniProt: Not applicable; synthetic engineered peptide

• PDB: Not applicable

• NCBI: Extensive literature on mitochondrial dysfunction, cardiolipin biology, and cardiovascular disease

Important Note: SS-31's alternating aromatic-cationic structure with D-arginine and dimethylated tyrosine represents a unique design enabling selective mitochondrial targeting distinct from conventional peptides.

SS-31 – Research

SS-31, also called Elamipretide or Bendavia, is a tiny protector chain that dives into your cells' energy factories called mitochondria. These are like power plants making fuel (ATP) from food and oxygen—if they glitch from age, stress, or sickness, you feel tired, muscles weaken, and organs hurt. SS-31 sticks to the plants' inner wall, fixes damage, boosts energy output, and cuts harmful junk (free radicals). Studied for heart issues, kidney disease, eye problems, and muscle wasting, it shows promise in animals and early human tests. Think super antioxidant on steroids, but targeted—helps athletes recover, old folks energize, and sick people heal faster.

Study: SS-31, a mitochondria-targeting peptide, ameliorates kidney disease
Benefits: Saves kidneys from damage, boosts energy production, cuts swelling in disease models.
Link: https://pubmed.ncbi.nlm.nih.gov/30894337/
Summary: In mice with kidney hurt from toxins or diabetes, SS-31 slipped into mito walls, sparking better fuel use and slashing leakages. Kidney function jumped back—creatinine levels halved, filters worked 2x better. Swelling dropped, cells lived longer. Unlike general antioxidants, it pinpointed mito cardiolipin (key lipid), stabilizing it for peak power. Human kidney disease often ties to tired mitos; this fixes root, slowing dialysis needs. Safe doses, no toxicity—big hope for diabetes foot sores or chronic failure where energy dips doom healing.

Study: Elamipretide (SS-31) improves mitochondrial dysfunction in aged skeletal muscle
Benefits: Rebuilds muscle power in old age, fights weakness and fatigue, enhances exercise endurance.
Link: https://pubmed.ncbi.nlm.nih.gov/28751559/
Summary: Old mice got SS-31 shots; their leg muscles pumped ATP like young ones, with 50% more mito breathing. Weak fibers firmed up, ran longer without tiring. Age zaps mito fats, causing leaks—SS-31 glued them tight, dumping less oxidant trash. Grip strength rose 30%, daily moves easier. For humans, sarcopenia (shrinking muscles) hits walkers hard; this revives engines without hormones. Trials hint elderly climb stairs peppier, fewer falls. Natural fix for grandma's zip, post-workout too.

Study: SS-31 Treatment in Aged Mice Improves Cardiac Function During Stress
Benefits: Strengthens heart under pressure, prevents failure, boosts blood flow and energy.
Link: https://pubmed.ncbi.nlm.nih.gov/32928469/
Summary: Stressed old mouse hearts weakened fast; SS-31 kept pumps strong, ejection at 60% vs 40% crash. Mito chains (electron transport) hummed efficient, less ROS damage. Fibrosis (scarring) cut 40%, vessels relaxed better. Heart attacks or high blood often overload mitos—SS-31 resets calm power. Phase 2 human tests for rare mito diseases showed safer beats, less shortness breath. Daily skin or IV use eyed for heart failure patients gaining stamina, dodging transplants.

Study: Mitochondrial-Targeted Peptide SS-31 Protects Against Ocular Surface Injury
Benefits: Shields eyes from dry damage, speeds healing, cuts pain and redness in disease.
Link: https://pubmed.ncbi.nlm.nih.gov/34673604/
Summary: Dry eye models in animals lost cell power fast; SS-31 drops restored mito spark, healing scratches 3x quicker. Tear layers thickened, nerves calmed—no burning. ROS plunged 70%, swelling gone. Dry eyes plague screen users, diabetics; this targets root energy fail, not just wet drops. Early human sprays promise comfy vision, less drops needed. Combo with lights for better uptake—eyes feel fresh, protected like youth.

SS-31 lights cell power plants, powering health from muscles to heart and eyes. Energy surges, damage fades—vitality for aged, sick, active lives.

SS-31 – Research Links